The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Increased Vascularity Detected by Digital Subtraction Angiography after VEGF Gene Transfer to Human Lower Limb Artery: A Randomized, Placebo-Controlled, Double-Blinded Phase II Study
Open accessAbstract
Vascular endothelial growth factor (VEGF) gene therapy may be useful for the treatment of lower-limb ischemia. The objectives of this study were to evaluate safety and angiographic and hemodynamic responses of local catheter-mediated VEGF gene therapy in ischemic lower-limb arteries after percutaneous transluminal angioplasty (PTA). For this study, we recruited patients with chronic lower-limb ischemia and atherosclerotic infrainguinal occlusion or stenosis suitable for PTA. In the study, 18 patients received 2x10(10) plaque-forming units (pfu) VEGF-adenovirus (VEGF-Ad), 17 patients received VEGF-plasmid/liposome (VEGF-P/L; 2000 microg of VEGF plasmid, 2000 microl of DOTMA:DOPE), and 19 control patients received Ringer's lactate at the angioplasty site. Digital subtraction angiography (DSA) was used to evaluate vascularity before, immediately after, and 3 months after the PTA. Clinical follow-up data, basic laboratory tests, and ankle-brachial index (ABI) were evaluated. Primary endpoint was DSA analysis of vascularity, and secondary endpoints were restenosis rate, Rutherford class, and ABI after 3 months follow-up. No major gene transfer-related side effects or differences in laboratory tests were detected between the study groups. However, anti-adenovirus antibodies increased in 61% of the patients treated with VEGF-Ad. For the primary endpoint, follow-up DSA revealed increased vascularity in the VEGF-treated groups distally to the gene transfer site (VEGF-Ad P=0.03, VEGFP/L P=0.02) and in the VEGF-Ad group in the region of the clinically most severe ischemia (P=0.01). As for the secondary endpoints, mean Rutherford class and ABI showed statistically significant improvements in the VEGF-Ad and VEGF-P/L groups, but similar improvements were also seen in the control patients. We conclude that catheter-mediated VEGF gene therapy is safe and well tolerated. Angiography demonstrated that VEGF gene transfer increased vascularity after PTA in both VEGF-Ad- and VEGF-P/L-treated groups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods for Rates and Proportions, 2nd ed
GROVE, W. A. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.12.1644-a · Cited by 3,748
Dvorak, H. F., Brown, L. F., Detmar, M. J., & Dvořàk, A. M. (1995) · Europe PMC (PubMed Central) · Cited by 3,115
Ferrara, N., & Henzel, W. J. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92678-8 · Cited by 2,268
Baumgartner, I., Pieczek, A., Manor, O., Blair, R., Kearney, M., Walsh, K., & Isner, J. M. (1998) · Circulation · doi:10.1161/01.cir.97.12.1114 · Cited by 1,098
Isner, J. M., Pieczek, A., Schainfeld, R., Blair, R., Haley, L., Asahara, T., Rosenfield, K., Razvi, S., Walsh, K., & Symes, J. F. (1996) · The Lancet · doi:10.1016/s0140-6736(96)03361-2 · Cited by 989
Losordo, D. W., Vale, P. R., Symes, J. F., Dunnington, C. H., Esakof, D. D., Maysky, M., Ashare, A. B., Lathi, K., & Isner, J. M. (1998) · Circulation · doi:10.1161/01.cir.98.25.2800 · Cited by 987
The measurement of interrater agreement
Fleiss, J. (1981) · Medical Entomology and Zoology · Cited by 864
Rosengart, T. K., Lee, L. Y., Patel, S. R., Sanborn, T. A., Parikh, M., Bergman, G. W., Hachamovitch, R., Szulc, M., Kligfield, P. D., Okin, P. M., et al. (1999) · Circulation · doi:10.1161/01.cir.100.5.468 · Cited by 656
Site-Specific Gene Expression in Vivo by Direct Gene Transfer into the Arterial Wall
Nabel, E. G., Plautz, G., & Nabel, G. J. (1990) · Science · doi:10.1126/science.2119055 · Cited by 569
Isner, J. M., Baumgartner, I., Rauh, G., Schainfeld, R., Blair, R., Manor, O., Razvi, S., & Symes, J. F. (1998) · Journal of Vascular Surgery · doi:10.1016/s0741-5214(98)70022-9 · Cited by 392
Cited by
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Hedman, M., Hartikainen, J., Syvänne, M., Stjernvall, J., Hedman, A., Kivelä, A., Vanninen, E., Mussalo, H., Kauppila, E., Simula, S., et al. (2003) · Circulation · doi:10.1161/01.cir.0000070540.80780.92 · Cited by 537
Self-citationVascular Endothelial Growth Factors
Ylä-Herttuala, S., Rissanen, T. T., Vajanto, I., & Hartikainen, J. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.053 · Cited by 480
Self-citationVascular Endothelial Growth Factor Signaling in Hypoxia and Inflammation
Ramakrishnan, S., Anand, V., & Roy, S. (2014) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-014-9531-7 · Cited by 442
Rissanen, T. T., Markkanen, J. E., Gruchala, M., Heikura, T., Puranen, A., Kettunen, M. I., Kholová, I., Kauppinen, R. A., Achen, M. G., Stacker, S. A., et al. (2003) · Circulation Research · doi:10.1161/01.res.0000073584.46059.e3 · Cited by 442
Gene transfer as a tool to induce therapeutic vascular growth
Ylä-Herttuala, S., & Alitalo, K. (2003) · Nature Medicine · doi:10.1038/nm0603-694 · Cited by 404
Self-citationKusumanto, Y. H., van Weel, V., Mulder, N. H., Smit, A. J., van den Dungen, J. J. A. M., Hooymans, J. M. M., Sluiter, W. J., Tio, R. A., Quax, P. H. A., Gans, R. O. B., et al. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.683 · Cited by 318
Viral gene therapy strategies: from basic science to clinical application
Young, L. S., Searle, P. F., Onion, D., & Mautner, V. (2006) · The Journal of Pathology · doi:10.1002/path.1896 · Cited by 313
Gene therapy progress and prospects: adenoviral vectors
St George, J. A. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302071 · Cited by 294
Human Studies of Angiogenic Gene Therapy
Gupta, R., Tongers, J., & Losordo, D. W. (2009) · Circulation Research · doi:10.1161/circresaha.109.200386 · Cited by 276
Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders
Shahryari, A., Saghaeian Jazi, M., Mohammadi, S., Razavi Nikoo, H., Nazari, Z., Hosseini, E. S., Burtscher, I., Mowla, S. J., & Lickert, H. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00868 · Cited by 262
VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond
Giacca, M., & Zacchigna, S. (2012) · Gene Therapy · doi:10.1038/gt.2012.17 · Cited by 252
Implications of vascular endothelial growth factor for postischemic neurovascular remodeling
Hermann, D. M., & Zechariah, A. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.100 · Cited by 162
Development of a surrogate angiogenic potency assay for clinical-grade stem cell production
Lehman, N., Cutrone, R., Raber, A., Perry, R., van't Hof, W., Deans, R., Ting, A. E., & Woda, J. (2012) · Cytotherapy · doi:10.3109/14653249.2012.688945 · Cited by 76
Katwal, A. B., Konkalmatt, P. R., Piras, B. A., Hazarika, S., Li, S. S., John Lye, R., Sanders, J. M., Ferrante, E. A., Yan, Z., Annex, B. H., et al. (2013) · Gene Therapy · doi:10.1038/gt.2013.16 · Cited by 56
The promotion of endothelial cell attachment and spreading using FNIII10 fused to VEGF-A165
Traub, S., Morgner, J., Martino, M. M., Höning, S., Swartz, M. A., Wickström, S. A., Hubbell, J. A., & Eming, S. A. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.04.050 · Cited by 42
Xiao, L., Yan, K., Yang, Y., Chen, N., Li, Y., Deng, X., Wang, L., Liu, Y., Mu, L., Li, R., et al. (2016) · Microvascular Research · doi:10.1016/j.mvr.2016.01.005 · Cited by 20
Hall, S., & Agrawal, D. K. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-017-0409-0 · Cited by 20
Metadata
- Authors
- Mäkinen, K., Manninen, H., Hedman, M., Matsi, P., Mussalo, H., Alhava, E., & Ylä-Herttuala, S.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2002-07
- Volume
- 6
- Issue
- 1
- Pages
- 127-133
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2083354706
- Cited by
- 374
- References
- 19
- FWCI
- 21.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.